# Forensic Dossier: Study Forensics: Amyloid-targeting antibody improves biomarkers without cognitive benefit

**Run ID:** `full27_study-forensics-029_Claude_Sonnet_c7eac2`  
**Task:** study-forensics-029 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T08:19:46.983742+00:00  
**Task Family:** solid  
**Trap Type:** borderline_solid_with_caveats  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Sonnet
**Winner:** Claude Sonnet — **71.5/100** (margin: 0.0)
**Failure modes:** missed_key_insight, named_not_explained, unsupported_conclusion, unsupported_intermediate_step
**Forensic flags:** 5
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Sonnet | 30.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 4.5/6 | 4.0/8 | 8.0/8 | 1.5/10 | 10.0/10 | **71.5/100** |

## Study Forensics Audit

### Claude Sonnet

**Classification:** `solid` [+] (gold: `solid`)
**Finding Recall:** 50%
**Matched Findings:** cautious_scope_control
**Missed Findings:** evidence_matches_claim
**Extra Findings:** none_or_minor, conclusion_exceeds_results, mechanism_not_demonstrated

## Reasoning Integrity Audit

### Claude Sonnet
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Sonnet
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Sonnet
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Sonnet

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "solid"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"
- **[MINOR]** `study_forensics_overflagging`: Agent raised extra findings in solid case: none_or_minor, conclusion_exceeds_results, mechanism_not_demonstrated


## Evidence Map

### Claude Sonnet

**Correctness:** 30.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 0.0/8
  - (-) `final_answer`: "solid"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[1]`: "Noted that the study found significant biomarker effects (reduced amyloid, improved neurodegeneration markers)"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[1]`: "The study measured both biomarkers (amyloid plaques, neurodegeneration markers) and cognitive outcomes"
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[1]`: "Whether the biomarker improvements were clinically meaningful"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.88"
    _Stated confidence level_
  - Note: 3 uncertainties (3 substantive)
  - Note: Confidence 0.88

**Alternative Hypothesis Quality:** 4.5/6
  - (+) `alternative_hypotheses[0]`: "Could be 'mechanism_vs_evidence' if investigators claimed cognitive benefits based only on biomarker changes"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 genuinely diverse alternatives

**Self Monitoring Quality:** 4.0/8
  - (+) `self_check[2]`: "Checked that I'm not fabricating problems where none exist - this appears to be honest reporting of mixed results"
    _Most substantive self-verification step_
  - Note: 3 self-check items
  - Note: Self-check quality: 0 deep, 3 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.71, 242 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "ne exist - this appears to be honest reporting of mixed results the study ap"
    _Insight 'honest reporting' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Sonnet

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "solid"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "solid"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "solid"
  - _Impacts: support_strength, structural_reasoning_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: evidence_matches_claim
  - `(task expectation)`: "Expected: evidence_matches_claim"
  - _Impacts: insight_depth_


## Consistency & Grounding Audit

### Claude Sonnet

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/8 content words)
  - `key_claims[0]`: "The study appropriately separates biomarker success from clinical efficacy"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/9 content words)
  - `key_claims[1]`: "Investigators acknowledge that cognitive benefits remain unproven despite biomarker improvements"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/9 content words)
  - `key_claims[2]`: "The research design appears methodologically sound with appropriate outcome measures"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "Could be 'mechanism_vs_evidence' if investigators claimed cognitive benefits based only on biomarker"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "Could be 'overclaim' if researchers overstated the clinical significance of biomarker improvements"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "solid"


## Agent Profiles

### Claude Sonnet (claude-sonnet-4-20250514)
**Parse OK:** True | **Latency:** 10625ms

**Final Answer:** solid

**Confidence:** 0.88

**Assumptions:**
- This is a Phase 2/3 randomized trial testing a monoclonal antibody
- The study measured both biomarkers (amyloid plaques, neurodegeneration markers) and cognitive outcomes
- The trial had adequate power to detect cognitive effects if they existed
- The investigators are being transparent about the mixed results

**Reasoning Steps:**
1. Identified that this is a well-designed randomized trial with appropriate primary and secondary endpoints
2. Noted that the study found significant biomarker effects (reduced amyloid, improved neurodegeneration markers)
3. Observed that the primary cognitive endpoint was negative - no slowing of cognitive decline
4. Evaluated the investigators' response: they acknowledged the cognitive benefits remain unproven while noting biomarker successes
5. Checked for overclaiming: investigators did not claim cognitive benefits despite biomarker improvements
6. Assessed transparency: researchers were honest about the trial's limitations and mixed results

**Key Claims:**
- The study appropriately separates biomarker success from clinical efficacy
- Investigators acknowledge that cognitive benefits remain unproven despite biomarker improvements
- The research design appears methodologically sound with appropriate outcome measures

**Alternative Hypotheses:**
- Could be 'mechanism_vs_evidence' if investigators claimed cognitive benefits based only on biomarker changes
- Could be 'overclaim' if researchers overstated the clinical significance of biomarker improvements

**Uncertainties:**
- The exact statistical power for cognitive endpoints
- Whether the biomarker improvements were clinically meaningful
- The duration of follow-up for cognitive assessments

**Self-Verification:**
- Verified that investigators did not claim cognitive benefits they couldn't support
- Confirmed that the separation of biomarker and cognitive outcomes was handled appropriately
- Checked that I'm not fabricating problems where none exist - this appears to be honest reporting of mixed results

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 4.5/6 `#######...`
- Self Monitoring Quality: 4.0/8 `#####.....`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Sonnet** scored **71.5/100**.

**Best per dimension:**
- Correctness: Claude Sonnet (30.0/30)
- Support Strength: Claude Sonnet (0.0/8)
- Structural Reasoning: Claude Sonnet (4.8/8)
- Assumption Discipline: Claude Sonnet (4.8/6)
- Uncertainty Handling: Claude Sonnet (3.9/6)
- Alternative Hypothesis Quality: Claude Sonnet (4.5/6)
- Self Monitoring Quality: Claude Sonnet (4.0/8)
- Insight Depth: Claude Sonnet (8.0/8)
- Mechanism Quality: Claude Sonnet (1.5/10)
- Communication Efficiency: Claude Sonnet (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Sonnet | 10.6s | 71.5/100 | 6.7 |

Failure modes observed: missed_key_insight, named_not_explained, unsupported_conclusion, unsupported_intermediate_step.
